Semaglutide vs Tirzepatide: Complete Comparison (2026)

Semaglutide and tirzepatide are the two most effective weight loss medications currently available — and for most people starting GLP-1 therapy, the choice between them is the single biggest decision in their treatment plan. Both are injected once a week. Both reduce appetite. Both have been studied in tens of thousands of patients. But they work differently, produce different amounts of weight loss, and come with different costs.

Here's what the clinical evidence actually shows, side by side.

Quick comparison

How they work

Both medications mimic natural gut hormones that are released after eating — but tirzepatide mimics two of them, which is why it's often more effective.

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. When you eat, your gut releases GLP-1, which signals fullness to your brain, slows stomach emptying so food stays in your stomach longer, and prompts the pancreas to release insulin. Semaglutide mimics GLP-1 but lasts much longer in the body than the natural hormone — a single weekly injection maintains steady levels.

Tirzepatide is a dual agonist. It activates the same GLP-1 receptor as semaglutide, plus a second receptor called GIP (glucose-dependent insulinotropic polypeptide). GIP is another gut hormone that plays a role in fat metabolism and energy balance. By hitting both receptors, tirzepatide produces stronger appetite suppression and greater weight loss than GLP-1 alone.

If you want a deeper look at the receptor biology behind both — what GLP-1 actually does in your gut and brain, why GIP matters, and where the science is heading next — read our explainer on how GLP-1 and GIP work.

Effectiveness: what clinical trials actually showed

The two pivotal studies are STEP 1 (semaglutide, 2021) and SURMOUNT-1 (tirzepatide, 2022). Both enrolled adults with obesity or overweight plus at least one weight-related condition. Both combined the medication with lifestyle counseling. Both ran for about 68–72 weeks.

STEP 1 (semaglutide 2.4 mg weekly):

• Average weight loss: 14.9% of body weight
• 50% of participants lost at least 15%
• 32% of participants lost at least 20%

SURMOUNT-1 (tirzepatide 15 mg weekly):

• Average weight loss: 20.9% of body weight
• 57% of participants lost at least 20%
• 36% of participants lost at least 25%

For a 220-lb starting weight, that's roughly 33 lbs lost on semaglutide vs 46 lbs on tirzepatide at one year. The weight loss projection calculator will model your specific starting point against either trial curve.

Dosing and titration

Both medications must be started at a low dose and increased gradually to minimize side effects — mostly nausea. Titrating too fast is the most common reason people quit GLP-1 therapy in the first month.

Semaglutide titration (Wegovy®):

1. Weeks 1–4: 0.25 mg
2. Weeks 5–8: 0.5 mg
3. Weeks 9–12: 1.0 mg
4. Weeks 13–16: 1.7 mg
5. Week 17+: 2.4 mg (maintenance)

Tirzepatide titration (Zepbound®):

1. Weeks 1–4: 2.5 mg
2. Weeks 5–8: 5 mg
3. Weeks 9–12: 7.5 mg
4. Weeks 13–16: 10 mg
5. Weeks 17–20: 12.5 mg
6. Week 21+: 15 mg (maintenance)

Some patients reach their goal weight at a lower dose and never need to reach the maximum. Your provider adjusts titration based on how you're tolerating each step.

Side effects compared

The side effect profiles are very similar — both medications share the same core mechanism. The difference is mostly a matter of intensity, since tirzepatide produces greater weight loss (and greater GI effects scale with weight loss).

Most common (both medications, affecting 20–40% of users in trials):

• Nausea (typically 1–4 weeks after each dose increase)
• Constipation
• Diarrhea
• Vomiting
• Abdominal discomfort

Less common but worth knowing:

• Fatigue (first few weeks)
• Loss of appetite to the point of under-eating (monitor protein intake)
• Injection site reactions (minor redness)
• Gallbladder issues (~1% of users; risk is higher with rapid weight loss)

Rare but serious (carry boxed warnings):

• Pancreatitis
• Thyroid C-cell tumors (based on animal studies; not conclusively linked in humans)
• Severe allergic reactions

Most GI side effects resolve within 4–8 weeks after starting the medication or after each titration step. For a deeper look, read our complete guide to GLP-1 side effects.

Cost comparison

This is usually the deciding factor for anyone paying out of pocket.

Brand-name pricing (without insurance)

With insurance coverage, these can drop to $25–150/month, but coverage for weight loss (non-diabetic indication) is inconsistent. Most commercial plans still don't cover weight-loss GLP-1s, and Medicare is prohibited by law from covering anti-obesity medications.

Compounded pricing

Compounded preparations of semaglutide and tirzepatide — prepared by US-licensed compounding pharmacies on a per-patient basis when a licensed provider determines they are clinically indicated — cost dramatically less than FDA-approved brand-name products. At Pallas, compounded semaglutide injection is a flat $269/mo; compounded oral semaglutide is $299/mo; compounded tirzepatide injection is $359/mo. All provider visits, dose adjustments, and shipping are included.

Which one should you choose?

There's no universally right answer — but there are patterns.

Tirzepatide tends to be better if:

• You have a significant amount of weight to lose (40+ lbs)
• Semaglutide hasn't worked well for you in the past
• You tolerated the titration schedule of other medications well
• Cost is not the primary constraint

Semaglutide tends to be better if:

• You're sensitive to medication effects and want a gentler titration
• Your goal is more moderate (20–30 lbs)
• You want the medication with the longest post-market safety data (approved 2 years earlier)
• You've seen friends or family succeed on it

Either works if:

• Budget drives the decision (compounded versions of both are roughly equivalent in cost at Pallas)
• Your doctor recommends it based on your health history

Where the class is heading (and why it matters today)

You may have seen recent headlines about next-generation weight-loss drugs producing even greater results than tirzepatide in clinical trials. Here's the honest read on what that means for someone making a decision in 2026.

The current direction in obesity medicine is straightforward: each generation of drug activates more receptors and produces more weight loss. Semaglutide hits one receptor (GLP-1). Tirzepatide hits two (GLP-1 + GIP). Investigational compounds currently in Phase 3 trials add a third — the glucagon receptor — and early data has shown substantial weight-loss effects that exceed tirzepatide's SURMOUNT-1 numbers.

A few caveats worth being clear about:

• None of these triple-receptor compounds are FDA-approved as of May 2026. They are investigational, available only through clinical trials, and several are still being evaluated for long-term safety.
• Approval timelines are typically multi-year. Even if Phase 3 trials succeed, an FDA-approved next-generation drug is likely years away from a pharmacy shelf.
• Adding receptors adds complexity, not just effectiveness. Glucagon activation has metabolic effects on heart rate, lean mass, and the liver that researchers are still characterizing.
• For now, semaglutide and tirzepatide are the highest-evidence options patients can actually start today. Both have years of post-market safety data and extensive published trial results.

The practical implication: it's reasonable to follow the research, but it's not reasonable to wait for it. Patients who would benefit from starting today have two excellent FDA-approved options with established track records, and either one can be switched or layered into a longer-term plan if better medications eventually reach the market.

Frequently asked questions

Can I switch from semaglutide to tirzepatide? Yes. This is fairly common — patients who plateau on semaglutide or want greater loss often switch. Your provider will design a transition schedule; typically you stop semaglutide and start tirzepatide at the lowest dose the following week.

Are the brand-name and compounded versions chemically identical? The active ingredient is the same compound. What differs is the formulation (concentration, inactive ingredients, preservatives) and the manufacturing oversight. Brand-name versions go through FDA approval; compounded versions are regulated by state boards of pharmacy and compounded per-patient.

Do I need to stay on GLP-1 therapy forever? The clinical evidence suggests weight is largely regained within a year of stopping, per the STEP 4 extension trial. Most patients treat GLP-1 therapy as long-term, similar to medications for blood pressure. Your provider will discuss maintenance strategies with you.

Which is more effective for appetite suppression? Tirzepatide is generally reported as more effective for appetite suppression, particularly at higher doses. The dual GLP-1 + GIP mechanism produces stronger satiety signaling in the brain.

Does insurance cover either one? Coverage varies enormously. Most commercial plans cover them for diabetes (Ozempic®, Mounjaro®) but not for weight loss (Wegovy®, Zepbound®). Medicare does not cover anti-obesity medications. Check your specific plan's formulary for weight-loss indications.

Can I take either during pregnancy? No. GLP-1 medications are contraindicated during pregnancy. Women of reproductive age using these medications should use effective contraception and discuss timing with their provider if planning pregnancy.

Bottom line: Tirzepatide produces more weight loss on average; semaglutide has a longer safety track record and gentler titration. Both work. The right choice depends on your goals, tolerance, and budget. A Pallas provider can help you decide — it takes about 2 minutes to start the intake.